Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Rhumatologie, la multitude des options

Abstract : The number of therapeutic antibodies available in rheumatology increases every year, mainly indicated in chronic inflammatory rheumatisms and other immune-mediated inflammatory diseases. The choice between all these monoclonal antibodies depends on their specificities, patients and diseases characteristics. Until now, there is no reliable biomarker, predictive of response for specialized medicine purpose. Today, therapeutic drug monitoring and anti-drug antibodies testing can help to better adapt the dose of the drug and to help in the decision to switch to another biological drug according to the activity of the inflammatory disease.
Liste complète des métadonnées
Contributeur : Nathalie Salvy-Cordoba <>
Soumis le : jeudi 26 mars 2020 - 12:57:00
Dernière modification le : mardi 9 juin 2020 - 03:33:01

Lien texte intégral




Jacques Morel, Denis Mulleman. Rhumatologie, la multitude des options. médecine/sciences, EDP Sciences, 2019, 35 (12), pp.1029-1033. ⟨10.1051/medsci/2019204⟩. ⟨hal-02519947⟩



Consultations de la notice